Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.

Gut microbes·2026
Same author

Fluorescent Aptamers Go Viral: Tracking the Coseparation of a SARS-CoV-2 RNA Fragment with the Nucleocapsid Protein Using the Encoded Mango II Tag.

ACS synthetic biology·2026
Same author

Duplication of the Antistasin-Like Structure Resulted in a New Anticoagulant Protein in the Medicinal Leech.

Biomolecules·2026
Same author

Beyond Direct Fibrinolysis: Novel Approaches to Thrombolysis.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Production, Purification, and Characterization of a Novel Cysteine-Rich Anticoagulant from the Medicinal Leech and the Functional Role of Its C-Terminal Motif.

Biomolecules·2025
Same author

Development of New Antimicrobial Peptides by Directional Selection.

Antibiotics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jan 7, 2026

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

2.2K

Recombinant RGD-Apoptins Decrease Human Melanoma Cell Viability.

Dmitriy Shirokov1,2, Daria Lepekhina1, Valentin Manuvera1,3

  • 1Lopukhin Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow 119435, Russia.

International Journal of Molecular Sciences
|December 30, 2025
PubMed
Summary
This summary is machine-generated.

Novel RGD-apoptin proteins show promise for treating melanoma. These engineered proteins target cancer cells specifically, inducing apoptosis while sparing healthy tissues, offering a potential new therapeutic strategy for this dangerous skin cancer.

Keywords:
MeWoRGD peptidesapoptinapoptosisdual-specificity oncolytic proteinsmelanomatherapeutic recombinant proteinstranscriptomicsαVβ3 integrins

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.3K
Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

6.0K

Related Experiment Videos

Last Updated: Jan 7, 2026

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

2.2K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.3K
Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

6.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • Cutaneous melanoma is a dangerous skin cancer with poor prognosis in advanced stages.
  • Malignant melanoma accounts for a small fraction of skin tumors but has a high mortality rate.
  • Developing novel therapeutic strategies for melanoma is a critical medical need.

Purpose of the Study:

  • To produce and evaluate novel recombinant proteins, RGD-apoptins, for anti-melanoma activity.
  • To assess the specificity and efficacy of RGD-apoptins in human cell models.
  • To investigate the mechanism of cell death induced by RGD-apoptins.

Main Methods:

  • Production of RGD-apoptins using an E. coli expression system.
  • Evaluation of RGD-apoptin cytotoxicity using resazurin and annexin V assays in melanoma cells, keratinocytes, and fibroblasts.
  • Transcriptomic analysis to study gene expression changes post-treatment.

Main Results:

  • RGD-apoptins significantly reduced the viability of MeWo human melanoma cells.
  • RGD-apoptins did not affect the viability of HaCaT human keratinocytes or primary skin fibroblasts, indicating specificity.
  • Cell death in melanoma cells was confirmed to occur via apoptosis.
  • Transcriptomic analysis provided dynamic insights into gene expression alterations.

Conclusions:

  • RGD-apoptins demonstrate specific anti-melanoma activity by inducing apoptosis in cancer cells.
  • The RGD peptide and apoptin components contribute to targeted delivery and tumor cell death.
  • These findings support the potential of RGD-apoptins as a targeted therapy for cutaneous melanoma.